«Duchenne muscular dystrophy (DMD) affects fewer than one in 6,000 newborn males every year.1 This rare genetic disorder is characterized by a progressive muscle breakdown, starting with those closest to the body’s core and moving to affect the extremities.2 Historically, the life expectancy of DMD carriers barely stretched beyond the teen years. New drug therapies, however, have extended that life span well into a patient’s 40s or 50s by slowing muscular degeneration and improving cardiac and lung function. For the small group of people affected by this disease, that development brings hope and the potential to improve their quality of life immensely.»

Article written by Simon Alfano, Christian Amberg, Nils Peters, Pablo Salazar, Marianne Vieux-Rochas, Sam Welton